Product Description
Insulin aspart is a short-acting, manmade version of human insulin. Insulin aspart works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. (Sourced from: https://medlineplus.gov/druginfo/meds/a605013.html)
Mechanisms of Action: INSR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 15
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: General Diabetes|Healthy Volunteers|Pregnancy Outcomes|Type 1 Diabetes|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04460326 |
In-FI | P3 |
Completed |
Type 2 Diabetes |
2023-05-27 |
78% |
2024-03-20 |
Primary Endpoints |
2018-004680-31 |
2018-004680-31 | P3 |
Completed |
Type 2 Diabetes|Type 1 Diabetes|Pregnancy Outcomes |
2023-03-23 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233759 |
CTR20233759 | P1 |
Completed |
Type 2 Diabetes |
2024-01-15 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230678 |
CTR20230678 | P1 |
Completed |
Type 2 Diabetes |
2023-11-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20160095 |
CTR20160095 | P1 |
Active, not recruiting |
Healthy Volunteers|General Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT05539872 |
API-I004-CL-B | P3 |
Completed |
Healthy Volunteers |
2023-01-29 |
8% |
2023-07-21 |
|
CTR20131062 |
CTR20131062 | P3 |
Recruiting |
Type 1 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131031 |
CTR20131031 | P3 |
Recruiting |
Type 1 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20212490 |
CTR20212490 | P3 |
Active, not recruiting |
Type 2 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20130086 |
CTR20130086 | P3 |
Active, not recruiting |
General Diabetes |
None |
2025-04-29 |
Treatments |
|
CTR20130087 |
CTR20130087 | P3 |
Active, not recruiting |
General Diabetes |
None |
2025-04-29 |
Treatments |
|
CTR20130088 |
CTR20130088 | P3 |
Active, not recruiting |
General Diabetes |
None |
2025-04-29 |
Treatments |
|
CTR20242041 |
CTR20242041 | P1 |
Completed |
Type 2 Diabetes |
2024-07-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233626 |
CTR20233626 | P3 |
Recruiting |
Type 2 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20240205 |
CTR20240205 | P1 |
Completed |
Type 2 Diabetes |
2024-05-29 |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/03/2025 |
News Article |
Insulin Analog Market Forecasting USD 25.29 Billion Valuation by 2034 |
|
10/16/2025 |
News Article |
Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options |
|
08/07/2025 |
News Article |
Governor Glenn Youngkin Announces $3 Million Grant to Support Civica's Affordable Insulin Programs |
|
07/15/2025 |
News Article |
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States |